Jonathan C. Javitt, Chief Scientist, 10% Owner at NRX Pharmaceuticals, Inc. (NRXP), bought 100,000 shares at $0.33 ($33K) on 2023-08-23, disclosed to the SEC on 2023-08-24.
Open-market purchase of $33k NRXP by Chief Scientist, 10% Owner. Below the thresholds we flag for high-conviction alerts (no C-suite role, rare reversal, cluster, or A-grade history). Context: insider career grade D.
Nothing distinguishes this filing.
| Filing → |
| NRXP | SELL | 2022-12-09 | $400K | — | Filing → |
| NRXP | BUY | 2022-06-02 | $5.8M | — | Filing → |
| NRXP | BUY | 2022-06-02 | $116K | — | Filing → |